Endoscopic sinus surgery, aspirin therapy effective for AERD management
USA: Endoscopic sinus surgery (ESS) coupled with aspirin therapy may help in long-term management of AERD in majority of patients, which rarely requires the T2 biologics incorporation, finds a recent study. Further, patient questionnaires such as outcomes measure test score may help in the identification of aspirin therapy failure and guide the practitioner in making a decision on when to introduce T2 biologics into the patient's treatment regimen.
The findings of the study are published in the journal Allergy and Asthma Proceedings.
Type 2 (T2) biologics and/or aspirin therapy are used for the management of aspirin-exacerbated respiratory disease (AERD). Auddie M. Sweis, Pritzker School of Medicine, Evanston, Illinois, and colleagues aimed to identify the number of patients with AERD who tolerated aspirin therapy, yet due to persistent symptoms, incorporated T2 biologic management.
For the purpose, the researchers performed a retrospective review between July 2016 and June 2019. It included patients with AERD and who underwent ESS, aspirin desensitization (AD), and at least 6 months of aspirin therapy (ATAD) after AD, and who remained biologic-naive up through this timepoint. A total of 103 patients met inclusion criteria.
The primary outcome was introduction of a T2 biologic while on ATAD.
Key findings of the study include:
- Two patients (1.9%) ultimately supplemented ATAD with a T2 biologic.
- The mean outcomes measure test score after 6 months of ATAD for patients who received biologics was 40.5 versus 15 in those who did not receive biologics.
- The mean differences between the postoperative predesensitization test score and the 6-month postdesensitization test score for patients who went on to receive biologics was an increase of 13 versus a decrease of 10 for those patients who did not receive biologics.
"ESS, coupled with AD and ATAD, was successful in the long-term management of the majority of the patients with AERD, which rarely required the incorporation of T2 biologics," wrote the authors.
"Patient questionnaires, such as outcomes measure test score, may identify aspirin therapy failures and help guide the practitioner in deciding when to introduce T2 biologics into the patient's treatment regimen."
Reference:
The study titled, "Effectiveness of endoscopic sinus surgery and aspirin therapy in the management of aspirin-exacerbated respiratory disease," is published in the journal Allergy and Asthma Proceedings.
DOI: https://www.ingentaconnect.com/content/ocean/aap/2021/00000042/00000002/art00008
